Pages Menu
FacebookTwitterPinterestRss
Categories Menu

IntraBio


This page is dedicated to news and information about IntraBio’s therapies for use in Niemann-Pick Disease Type C (NPC). Information is released as it becomes available.

CLINICALTRIALS.GOV

ABOUT INTRABIO     GLOSSARY OF TERMS



IntraBio IB1001-201 Clinical Trial for NPC Reaches 2/3 of their Recruitment Goal

.
CLICK HERE FOR COMPLETE ANNOUNCEMENT

11/13//2019 jjb

IntraBio Clinical Trial IB1001-201 Open for US Recruitment at Mayo Clinic

.
CLICK HERE FOR COMPLETE ANNOUNCEMENT

09/04/2019 jjb

IntraBio IB1001 Series Update

.
IntraBio is developing a number of small-molecule drug candidates that have broad applicability to rare and common neurological disorders, genetic, and inflammatory diseases. Their current lead drug candidate, IB1001, is initially being developed to treat three rare, genetic diseases where there are extremely high unmet medical needs: Niemann-Pick disease type C, GM2 Gangliosidosis (Tay-Sachs and Sandhoff Disease), and Ataxia-Telangiectasia (A-T; an inherited Cerebellar Ataxia). Click the link below for additional information.

.
CLICK HERE FOR IB1000 SERIES DEVELOPMENT HISTORY

05/31/2019 jjb

NNPDF Industry Update Webinar Series featuring IntraBio, Inc.

.
CLICK HERE FOR RECORDING

04/25/2019 jjb

IntraBio Clinical Trial Authorization Application Approved by the MHRA for the Treatment of NPC

.
CLICK HERE FOR COMPLETE ANNOUNCEMENT

03/11/2019 jjb

IntraBio Investigational New Drug Application Approved by the FDA for the Treatment of NPC

.
CLICK HERE FOR COMPLETE ANNOUNCEMENT

02/13/2019 jjb

IntraBio Receives Niemann-Pick Disease Orphan Drug Designation from the FDA for IB1000 Series

.
CLICK HERE FOR COMPLETE ANNOUNCEMENT

11/26/2018 jjb